WO2009005045A1 - Substituted dihydroisoquinoline derivative - Google Patents

Substituted dihydroisoquinoline derivative Download PDF

Info

Publication number
WO2009005045A1
WO2009005045A1 PCT/JP2008/061876 JP2008061876W WO2009005045A1 WO 2009005045 A1 WO2009005045 A1 WO 2009005045A1 JP 2008061876 W JP2008061876 W JP 2008061876W WO 2009005045 A1 WO2009005045 A1 WO 2009005045A1
Authority
WO
WIPO (PCT)
Prior art keywords
acceptable salt
pharmacologically acceptable
pharmaceutical agent
intracellular signaling
dihydroisoquinoline derivative
Prior art date
Application number
PCT/JP2008/061876
Other languages
French (fr)
Japanese (ja)
Inventor
Shoichi Saito
Yukari Onishi
Junko Sasaki
Taketoshi Ogawa
Shiho Kozuma
Osamu Ando
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of WO2009005045A1 publication Critical patent/WO2009005045A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are: a substituted dihydroisoquinoline derivative which can inhibit intracellular signaling or cell activation induced by an endotoxin or a cell response (e.g., the excess production of an inflammatory mediator) induced by the intracellular signaling or the cell activation, or a pharmacologically acceptable salt thereof; a pharmaceutical agent comprising the substituted dihydroisoquinoline derivative or the pharmacologically acceptable salt thereof as an active ingredient; a method for producing the substituted dihydroisoquinoline derivative or the pharmacologically acceptable salt thereof or the pharmaceutical agent; and a pharmaceutical agent useful for the prevention and/or treatment of a disease associated with intracellular signaling or cell activation induced by an endotoxin or a cell response induced by the intracellular signaling or the cell activation, such as sepsis (including septic shock, disseminated intravascular coagulation, multiple organ failure), which comprises the substituted dihydroisoquinoline derivative as an active ingredient. Specifically disclosed are: a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof; and a pharmaceutical agent comprising the compound as an active ingredient.
PCT/JP2008/061876 2007-07-04 2008-07-01 Substituted dihydroisoquinoline derivative WO2009005045A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007175959 2007-07-04
JP2007-175959 2007-07-04

Publications (1)

Publication Number Publication Date
WO2009005045A1 true WO2009005045A1 (en) 2009-01-08

Family

ID=40226089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061876 WO2009005045A1 (en) 2007-07-04 2008-07-01 Substituted dihydroisoquinoline derivative

Country Status (2)

Country Link
TW (1) TW200914012A (en)
WO (1) WO2009005045A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012063099A1 (en) 2010-11-08 2012-05-18 Telefonaktiebolaget L M Ericsson (Publ) Method and apparatus for enabling dns redirection in mobile telecommunication systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11147876A (en) * 1997-09-12 1999-06-02 Kanebo Ltd Tetrahydroisoquinoline derivative and medicine containing the same as active ingredient
JP2001518090A (en) * 1997-03-28 2001-10-09 ゼネカ リミテッド Hydroxamic acids substituted by heterocycles useful for inhibiting tumor necrosis factor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518090A (en) * 1997-03-28 2001-10-09 ゼネカ リミテッド Hydroxamic acids substituted by heterocycles useful for inhibiting tumor necrosis factor
JPH11147876A (en) * 1997-09-12 1999-06-02 Kanebo Ltd Tetrahydroisoquinoline derivative and medicine containing the same as active ingredient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARSANYI K. ET AL.: "Isobasic isoquinolines. I. Derivatives of 2- (hydroxyimino)-2-(1-isoquinolinyl)acetic acid and their reduction products", JUSTUS LIEBIGS ANNALEN CHEMIE, vol. 10, 1973, pages 1606 - 1611 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012063099A1 (en) 2010-11-08 2012-05-18 Telefonaktiebolaget L M Ericsson (Publ) Method and apparatus for enabling dns redirection in mobile telecommunication systems

Also Published As

Publication number Publication date
TW200914012A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
TW200728307A (en) Novel spirochromanone derivatives
WO2008110314A8 (en) Fluoralkylphenylamidines and their use as fungicides
WO2006121941A3 (en) Pharmaceutical compositions comprising imatinib and a release retardant
WO2008005368A3 (en) Piperazines as p2x7 antagonists
NO20072978L (en) New betuene derivatives, their preparation and their use
WO2006113552A8 (en) Cyanoarylamines
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
NO20090075L (en) New CXCR2 inhibitors
WO2009060835A1 (en) Novel ubiquilin-binding small molecule
EP1704856A4 (en) Hsp90 family protein inhibitor
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2008059370A8 (en) Substituted bicyclocarboxyamide compounds
WO2007126900A3 (en) Antifungal agents
BRPI1011804A2 (en) pharmaceutical composition with improved solubility
MX2009010302A (en) Indole derivative having cpla2 inhibitory activity, use of the same and method for producing the same.
EA201270359A1 (en) THERAPEUTIC MEANS FROM MOOD DISORDERS
WO2007023342A3 (en) Process of making geminal bisphosphonic acids and pharmaceutically acceptable salts and/or hydrates thereof
EA201071395A1 (en) TOLERANCE INHIBITOR TO ANALGETICS
WO2008155666A3 (en) Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2008153129A1 (en) Agent for lowering uric acid level
EP1650194A4 (en) Protein kinase inhibitor
WO2007097888A3 (en) Fluoroquinolone carboxylic acid salt compositions
WO2008093838A1 (en) Pyridyl imidazolidine derivative having sulfamoyl group, and pharmaceutical use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777727

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08777727

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP